Ocugen Inc (OCGN)

[ALERTS100%to10000%GAIN]

Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present virtually to provide an update on the development of Ocugen’s breakthrough modifier gene therapy platform as well as its novel biologic product candidate. He will highlight Ocugen’s lead product candidate, OCU400, which has the potential to treat many forms of retinitis pigmentosa and just received its fourth FDA orphan drug designation. Dr. Musunuri will share Ocugen’s recent accomplishments and its upcoming planned near and medium-term milestones.

Presentation Details:
Date: Tuesday, September 15, 2020
Time: 03:00 PM (Eastern Time)
Webcast Link: https://wsw.com/webcast/hcw7/ocgn/1597167